Loading
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Previous close
$5.97
+$0.34 · +6.04%
Regular session · ET · Market data may be delayed.
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Day range
Current $5.97
52-week range
Current $5.97
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
28
Expensive
Sentiment
52
Mixed
Risk
82
Extreme Risk
Momentum
18
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Day range
Current $5.97
52-week range
Current $5.97
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.04M USD | 2.14M USD | 2.09M USD | 2.08M USD | 1.42M USD |
| Cost of goods sold | 1.47M USD | 1.44M USD | 1.22M USD | 1.33M USD | 917.84K USD |
| Gross profit | 566.31K USD | 699.3K USD | 862.11K USD | 750.41K USD | 504.31K USD |
| Research and development | 1.89M USD | 3.12M USD | 1.96M USD | 982.23K USD | 411.38K USD |
| Selling, general, and administrative | 6.99M USD | 4.27M USD | 3.77M USD | 3.92M USD | 4.02M USD |
| Operating expenses | 8.88M USD | 7.39M USD | 5.73M USD | 4.9M USD | 4.43M USD |
| Interest income | — | 191.67K USD | 16.85K USD | — | — |
| Interest expense | 22.54K USD | 21.41K USD | 75.82K USD | 8.29K USD | 118.42K USD |
| Depreciation and amortization | 193.8K USD | 285.05K USD | 287.72K USD | 368.96K USD | 318.26K USD |
| Operating income | −8.32M USD | −6.69M USD | −4.87M USD | −4.15M USD | −3.93M USD |
| Net income | −8.23M USD | −10.48M USD | −5.49M USD | −4.81M USD | −8.42M USD |
Company facts updated Sep 5, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
